A pharmacodynamics question often contains only a few experimental observations: one curve moves to the right, another reaches a lower plateau, or a second drug reduces an agonist’s effect. The task is to translate those observations into a mechanism without confusing potency, efficacy and affinity.
This guide gives you a repeatable method, numerical examples and five original single-best-answer questions. The examples describe hypothetical laboratory systems, not prescribing instructions. For a wider revision schedule, use our complete MRCEM Primary revision guide.
1. Start with the experiment and the axes
Pharmacodynamics versus pharmacokinetics
Pharmacodynamics connects drug exposure with biological effect. Pharmacokinetics concerns how exposure changes through absorption, distribution, metabolism and elimination. In an isolated-tissue experiment, the investigator may control concentration directly. In a patient, the same administered dose need not produce the same concentration at the target. Read the horizontal axis before interpreting the result. [15]
If the stem asks about loading dose or clearance, use the pharmacokinetics calculations guide. If it asks what happens to a response when a receptor ligand is added, begin with the pharmacodynamic observations.
Read a graded concentration–response curve
A graded curve records the size of a response, such as muscle contraction. The horizontal axis often shows concentration on a logarithmic scale; the vertical axis shows effect. Emax is the maximum response. EC50 is the concentration producing half that drug’s maximum response in that experimental system. [4]
A useful reading order is: identify the measured effect, check units and scaling, locate each plateau, then compare concentrations at a stated response. Do not decide what the drug is doing from the position of one isolated point.
Check the current MRCEM Primary syllabus
RCEM currently describes MRCEM Primary as 180 SBAs in three hours. The updated Basic Sciences Syllabus was launched on 28 October 2026 and applies from 21 April 2027 onwards. Read the official syllabus for your sitting. This tutorial supports understanding of drug action; it does not predict a particular number of receptor or curve questions. [1][2]
2. Separate potency, efficacy and affinity
Potency: how much is required?
Potency describes the dose or concentration required for a specified effect. For comparable agonist curves, a lower EC50 indicates greater potency. It does not tell you that a drug produces a larger maximum effect, lasts longer or is safer. Potency reflects more than binding affinity alone. [5][25]
Efficacy: how large is the response?
When comparing agonists in the same system, the plateau provides a practical measure of maximal efficacy. Two drugs can reach the same plateau while requiring different concentrations. Conversely, a drug can have a low EC50 yet a lower maximum response. Always state the tissue and endpoint being compared. [6]
Affinity: binding is not activation
Affinity concerns binding to the receptor. A ligand can bind strongly without activating it. The equilibrium dissociation constant, Kd, relates to binding; in a simple binding model a lower Kd indicates higher affinity. EC50 instead measures a functional response. Do not replace one with the other merely because both are concentrations. [7][13]
Term | Question to ask | Common mistake |
|---|---|---|
Potency | What concentration produces the specified response? | Calling the smallest-dose drug the most effective |
Maximal efficacy | How high does the response plateau? | Judging efficacy from horizontal position |
Affinity | How readily does the ligand bind? | Assuming binding guarantees activation |
3. Work through a numerical comparison
Compare drugs with the same maximum first
Consider these invented results from one tissue preparation, using the same assay and concentration units. The response is measured on a common scale; it has not been separately normalised to 100% for each drug.
Drug | EC50 | Emax |
|---|---|---|
A | 2 nmol/L | 100 response units |
B | 20 nmol/L | 100 response units |
C | 1 nmol/L | 40 response units |
A and B have the same maximum response. A requires one tenth of B’s concentration to reach 50 units, so A is ten times as potent by this comparison: 20 ÷ 2 = 10. Their different EC50 values do not establish different maximal efficacy.
Use each drug’s own maximum when finding EC50
For C, half-maximal response is 20 units, because its maximum is 40. Its EC50 of 1 nmol/L therefore refers to 20 units, not 50. C has a lower EC50 but cannot reach A’s or B’s 100-unit maximum in this experiment. Comparing EC50 values alone would conceal that limitation.
If the question asks which drug needs less concentration to produce a particular absolute effect, compare both curves at that effect. An effect above C’s ceiling cannot be used to calculate an equipotent concentration for C. This is why the specified endpoint matters. [14]
4. Full agonists, partial agonists and inverse agonists
A partial agonist is not simply a small dose of a full agonist
A full agonist can produce the system’s maximum response. A partial agonist has a lower maximum in the same system, even at high receptor occupancy. Increasing its concentration does not turn it into a full agonist. The classification depends on the receptor system and response measured. [8]
Why a partial agonist can oppose a full agonist
When both ligands act at the same receptor, the partial agonist can occupy sites that would otherwise be occupied by the full agonist. The combined response may therefore fall. Its effect depends on what is already present: it can stimulate an otherwise unstimulated system while reducing the response to a full agonist. [9]
Imagine a teaching experiment in which ligand P alone gives a modest contraction. When P is added to a preparation already exposed to full agonist F, contraction falls. Those observations are compatible with partial agonism. Calling P a neutral antagonist would fail to explain why P produced a response on its own.
Inverse agonism requires baseline receptor activity
Some receptors signal in the absence of added agonist. An inverse agonist reduces that constitutive activity. A neutral antagonist blocks agonist action without reducing the baseline activity through inverse agonism. “Opposite clinical effect” is not enough to establish inverse agonism: the evidence must concern the receptor’s baseline signalling. [26]
5. Interpret antagonism from what changes
Reversible competitive antagonism: right shift, preserved maximum
In the standard equilibrium model, a reversible competitive antagonist competes at the agonist’s binding site. More agonist is needed for the same effect, giving a parallel rightward shift with preserved Emax. The antagonism is surmountable in this experimental model. [10]
For example, an agonist’s EC50 rises from 4 to 24 nmol/L after an antagonist is added, while the maximum remains 80 units. The concentration ratio is 24 ÷ 4 = 6. The agonist now needs six times the concentration for its half-maximal response; the maximum has not fallen. This laboratory relationship is not a recommendation to escalate a patient’s dose.
Non-competitive and irreversible are different descriptions
Non-competitive antagonism can prevent an agonist’s response through a different binding site or mechanism. Irreversible antagonism describes persistent receptor inactivation that cannot simply be displaced. An irreversible ligand may occupy the agonist’s own site. These descriptions can overlap, but non-competitive does not automatically mean covalent or irreversible binding. [11][12]
A reduced maximum that cannot be restored by more agonist supports insurmountable antagonism in a suitable experiment. It does not, by itself, identify the binding site or prove irreversibility. Distinguish what the curve demonstrates from what the stem additionally tells you about binding or recovery.
Spare receptors explain an important exception
Some systems achieve maximum effect without occupying every receptor. This receptor reserve helps explain why EC50 can be lower than Kd. It also means that inactivating some receptors need not immediately lower the maximum: the remaining functional receptors may initially sustain it. Once the reserve is exhausted, further loss can depress Emax. [13]
Observation | Best initial interpretation | Qualification |
|---|---|---|
Parallel right shift; same Emax | Compatible with reversible competitive antagonism | Assumes the usual equilibrium model |
Lower Emax despite more agonist | Compatible with insurmountable antagonism | Does not uniquely identify the mechanism |
Low maximum from a ligand acting alone | Consider partial agonism | Compare the same tissue and endpoint |
Baseline signalling falls without added agonist | Consider inverse agonism | Baseline constitutive activity must be present |
6. Avoid the most common curve-reading errors
Do not confuse graded and quantal responses
A graded response measures magnitude. A quantal response classifies whether a specified outcome occurred and can plot the proportion of a population responding. In a quantal experiment, ED50 denotes the median effective dose: 50% meet the defined endpoint. That is different from half of one preparation’s maximum response. [14]
Do not read logarithmic spacing as addition
On a concentration axis labelled 1, 10, 100 and 1,000, equally spaced ticks represent multiplication by ten. Moving from 10 to 100 is not the same numerical increment as moving from 100 to 1,000. Read the labels instead of estimating concentration from an assumed linear ruler.
Do not infer clinical superiority from a curve alone
The curve reports an endpoint under particular conditions. It does not contain a complete benefit–harm assessment, a duration of action or a treatment recommendation. When revising, write down exactly which conclusion the data justify before inspecting the answer options.
7. Five original MRCEM Primary-style SBAs
These independently written educational questions are not official, recalled or endorsed RCEM material. Choose one answer before reading the explanations. Assume the same experimental conditions throughout each question.
Question 1: Same plateau, different concentration
Agonists X and Y each produce a maximum contraction of 60 units. Their EC50 values are 3 and 30 nmol/L respectively. Which statement is best supported?
Question 2: Identify the interaction
Adding ligand Z produces a parallel right shift of a full agonist’s concentration–response curve. Emax is unchanged and increasing agonist concentration restores the response. Which mechanism best fits the standard equilibrium model?
Question 3: Find the correct half-maximum
A full agonist produces a maximum of 120 units. A partial agonist in the same preparation produces a maximum of 48 units. At which response should the partial agonist’s EC50 be read?
Question 4: Binding without a reduced maximum
A preparation still reaches its original maximal response after an irreversible antagonist has inactivated a proportion of its receptors. Which explanation is most appropriate?
Question 5: Activity below baseline
A receptor system has measurable constitutive activity without added agonist. Ligand Q reduces that activity below baseline. Which description best fits Q?
Answers and explanations
Question 1: B The ratio is 30 ÷ 3 = 10. X needs less concentration for the same half-maximal effect. A confuses concentration with the plateau. C cannot be inferred from these functional measurements. D concerns elimination, which is not measured. E contradicts the stated maximum.
Question 2: A The combination of surmountability and preserved Emax fits reversible competitive antagonism. B and C would be expected to reduce the attainable maximum in the stated circumstances. D would abolish the receptor-mediated response. E predicts needing less, not more, agonist.
Question 3: B Half of the partial agonist’s own maximum is 48 ÷ 2 = 24 units. A is one quarter of its maximum. C is its full maximum. D incorrectly uses half of the full agonist’s maximum. E uses the full agonist’s complete response and is unattainable by the partial agonist here.
Question 4: C Spare receptors can allow the remaining receptors to support the original maximum. A is unnecessary and contradicts the stated irreversible interaction. B introduces an unmeasured pharmacokinetic change. D is not a general consequence of antagonist exposure. E is false: response and occupancy need not have the same midpoint.
Question 5: D Reducing constitutive receptor activity is the defining observation. A and B would increase activity through positive agonism. C does not explain the reduction in constitutive signalling. E is unrelated to the receptor observation and cannot be inferred.
8. Consolidate your pharmacodynamics revision
Use a short interpretation checklist
Before selecting an answer, state the endpoint, compare maxima, compare the relevant concentrations and identify whether the interaction is surmountable. Finally, check that your explanation accounts for every observation. A good answer should explain both what changed and what remained intact.
Turn mistakes into a specific learning target
If you confuse EC50 with Emax, practise comparing two curves with the same plateau. If you misread partial agonists, calculate half of each drug’s own maximum. If you overinterpret antagonism, separate the experimental observation from the proposed mechanism. Reattempt the question later without the options visible.
Practise with StudyMedical
Build on these examples with the StudyMedical MRCEM Primary question bank. It offers over 7,800 questions, explanations with teaching diagrams, topic-based custom quizzes, timed quizzes and the option to revisit previously incorrect answers. You can also try free sample questions without signing up. [16]
